Recombinant human granulocyte stimulating factor Recombinant human granulocyte stimulating factor, used to promote white blood cell production in patients with leucopenia, has been proposed for ALS as the GSF receptor is expressed by motor neurons, has neurotropic consequences, and shields classy motor neuronal cells from apoptosis. Larger studies are expected. Recombinant human hepatocyte growth factor Recombinant human hepatocyte growth factor has, along with its neurotropic consequences, antiapoptotic and antiglutammatergic properties. Gene therapy and supplier Doxorubicin Intrathecal aministration dramatically prolonged survival in different studies on SOD1 animal models, even when provided at symptom onset. C65 A recently available immunohistochemical study on both familial and sporadic ALS discovered that HGF is expressed on the anterior horn cells of the back, supporting the hypothesis that disruption of HGF program therefore adds to the speed of neuronal damage in FALS individuals. Nevertheless, safety or eff icacy data in patients with ALS miss and the substance needs intrathecal administration. Brain derived neurotrophic Organism factor Brain derived neurotrophic factor is a neurotrophin that supports the growth and survival of developing motor neurons. Preclinical studies in several animal models discovered that BDNF treatment significantly prolongs survival and decreases the increased loss of motor nerves. In phase I/II study, the subcutaneous infusion of BDNF increased survival and retard loss of pulmonary function in ALS patients, but a large phase III placebo-controlled clinical trial of subcutaneous administration of 25 or 100 g/kg d 1. 135 ALS people failed to demonstrate a statistically significant effect of BDNF on success. 71 Post hoc analyses revealed a statistically significant benefit in ALS patients having an early respiratory disability. Higher subcutaneous dosage or an intrathecal delivery have already been proposed to highlight the possible CTEP beneficial results of the drug. Recently, in a stage I/II test intrathecal infusion of recombinant methionyl human BDNF in doses of up to 150 g/day showed well tolerated and safe effects in 25 ALS patients, although reversible mild sensory symptoms were reported in the larger dosage subgroup. 67 Studies on the efficacy of intrathecal BDNF are for that reason required. Glial cell derived neurotrophic factor Glial cell derived neurotrophic factor features a strong trophic impact on motor nerves. Several preclinical in vitro and in vivo studies discovered that therapy with GDNF mediated by both an adeno associated virus vector C74 or by mesenchimal stem cells is effective in extending engine neurons emergency. However, reports from patients with sporadic ALS gave contradictory results.